RTNS 2012
Recent articles
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Explore more from The Transmitter
How artificial agents can help us understand social recognition
Neuroscience is chasing the complexity of social behavior, yet we have not answered the simplest question in the chain: How does a brain know “who is who”? Emerging multi-agent artificial intelligence may help accelerate our understanding of this fundamental computation.
How artificial agents can help us understand social recognition
Neuroscience is chasing the complexity of social behavior, yet we have not answered the simplest question in the chain: How does a brain know “who is who”? Emerging multi-agent artificial intelligence may help accelerate our understanding of this fundamental computation.
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.